<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357797</url>
  </required_header>
  <id_info>
    <org_study_id>14-465</org_study_id>
    <nct_id>NCT02357797</nct_id>
  </id_info>
  <brief_title>Adjunctive Vortioxetine in Schizophrenia</brief_title>
  <acronym>AVIS</acronym>
  <official_title>Adjunctive Vortioxetine in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study&#xD;
      comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88&#xD;
      stable patients with a research diagnosis of schizophrenia determined with the Structured&#xD;
      Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness&#xD;
      duration (i.e., &lt;/=5 years and &gt;5 years) in order to allow for post-hoc analyses examining&#xD;
      whether earlier illness moderates greater negative and /or cognitive symptom reduction in&#xD;
      response to vortioxetine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study&#xD;
      comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88&#xD;
      stable patients with a research diagnosis of schizophrenia determined with the Structured&#xD;
      Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness&#xD;
      duration (i.e., &lt;/=5 years and &gt;5 years) in order to allow for post-hoc analyses examining&#xD;
      whether earlier illness moderates greater negative and /or cognitive symptom reduction in&#xD;
      response to vortioxetine.&#xD;
&#xD;
      Patients with clinical stability for at least 3 months and stable antipsychotic and&#xD;
      psychotropic medication treatment for at least the last 4 weeks and without relevant&#xD;
      depression, positive psychotic symptoms or extrapyramidal symptoms EPS will be eligible.&#xD;
      After written informed consent, patients will undergo a screening visit to confirm full study&#xD;
      eligibility. If all in- and exclusion criteria are fulfilled, patients will undergo a&#xD;
      baseline assessment and then be randomized 1:1 to 16 weeks of adjunctive treatment with&#xD;
      vortioxetine or placebo. Subsequently, patients will be seen at week 1, 2, 4 and monthly for&#xD;
      the next 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Negative Symptom Assessment Scale (NSA-16) total score from baseline to endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the general composite score on the MATRICS Consensus Cognitive Battery (MCCB) from baseline to endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Negative Symptoms</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient&#xD;
&#xD;
          2. SCID diagnosis of schizophrenia&#xD;
&#xD;
          3. Age 18-65 years old&#xD;
&#xD;
          4. Treated with an adequate dose of one or a maximum of two antipsychotic medications for&#xD;
             at least 3 months, with a stable dose for at least the last 4 weeks, and willing to&#xD;
             continue for up to 16 weeks.&#xD;
&#xD;
          5. No antidepressant treatment for at least 8 weeks prior to randomization.&#xD;
&#xD;
          6. Treatment with other concomitant, non-antipsychotic, psychiatric medications is&#xD;
             allowed, but must be unchanged for at least 8 weeks, with a stable dose for at least&#xD;
             the last 4 weeks, and willing to continue for 16 weeks. Benzodiazepines must not be&#xD;
             given within 8 hours of the cognitive assessment. Treatment with non-psychiatric&#xD;
             medications is unrestricted.&#xD;
&#xD;
          7. PANSS Negative subscore &gt;14 with at least two of the items at a level &gt;/=4 (moderate)&#xD;
&#xD;
          8. PANSS Positive subscore &lt;/=14 with not more than one of the items at a level &gt;/=4&#xD;
             (moderate) for patients who have been stable outpatients for &lt;1 year. A PANSS Positive&#xD;
             subscore of &lt;/=18 is acceptable for patients who have been stable outpatients for&#xD;
             &gt;/=1year and whose psychotic symptoms do not affect behavior in a clinically relevant&#xD;
             way as per investigator assessment. - . In order to avoid simple double counting, any&#xD;
             rating on P1 (&quot;delusions&quot;) will not be considered as an additional symptom for&#xD;
             determination of eligibility based on PANSS positive subscore when a specific delusion&#xD;
             is present that is rated either on P5 (&quot;grandiosity&quot;) or P6&#xD;
             (&quot;suspiciousness/paranoia&quot;), whereas delusions not captured by P5 (&quot;grandiosity&quot;) or&#xD;
             P6 (&quot;suspiciousness/paranoia&quot;), will be rated under P1 (&quot;delusions&quot;) and counted&#xD;
             toward the sum score used to determine study eligibility).&#xD;
&#xD;
          9. HAMD-17 total score &lt;/=12&#xD;
&#xD;
         10. Simpson Angus Score of any item &lt;3&#xD;
&#xD;
         11. English-speaking&#xD;
&#xD;
         12. Competent and willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Structural brain disease&#xD;
&#xD;
          2. Mental retardation by history and estimated IQ &lt;70 (WRAT-III Word Reading)&#xD;
&#xD;
          3. Autism-spectrum disorder diagnosis by history&#xD;
&#xD;
          4. Any serious chronic medical illnesses that in the view of the investigator will&#xD;
             interfere with the patient's ability to comply with the study procedures or that will&#xD;
             interfere with cognition.&#xD;
&#xD;
          5. Active substance abuse or dependence in the past 8 weeks&#xD;
&#xD;
          6. Intolerance to or inefficacy of vortioxetine in the past&#xD;
&#xD;
          7. Acute anger to self or others as per investigator assessment&#xD;
&#xD;
          8. Pregnant or breastfeeding females&#xD;
&#xD;
          9. Unwilling or unable to be sexually abstinent or not using an effective form of birth&#xD;
             control if they are sexually active&#xD;
&#xD;
         10. Current treatment with a Monoamine Oxidase Inhibitor (MAOI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph U Correll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore LIJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph U Correll, MD</last_name>
    <phone>718-470-4812</phone>
    <email>ccorrell@nshs.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Guinart, MD</last_name>
    <phone>718-470-4139</phone>
    <phone_ext>4139</phone_ext>
    <email>DGuinart@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henderson Behavioral Health</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saiqa Ismail, MD</last_name>
      <email>sismail@hendersonbh.org</email>
    </contact>
    <contact_backup>
      <last_name>Elise Ward, RN, MSW</last_name>
      <phone>954-730-7284</phone>
      <phone_ext>2813</phone_ext>
      <email>eward@hendersonbh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cherry Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Achtyes, MD</last_name>
      <phone>616-965-8253</phone>
      <email>EricAchtyes@cherryhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Roshanah Dayton</last_name>
      <phone>616-965-8200</phone>
      <phone_ext>7169</phone_ext>
      <email>RoshanahDayton@cherryhealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph U Correll, MD</last_name>
      <phone>718-470-4812</phone>
      <email>ccorrell@nshs.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Christoph U. Correll, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

